Eurofins Scientific Shares Under Pressure: Down 15.54% Over the Week at €58.58
Eurofins Scientific shares fell by 1.97% to €58.58 this Wednesday, April 29, 2026, in mid-afternoon trading, extending a marked downward trend. Over the past seven days, the stock has seen a decline of 15.54%, in a Paris market that is itself trending downward, with the CAC 40 dropping 0.19% during the session.
At €58.58, Eurofins Scientific's share price is now below the lower Bollinger Band threshold set at €59.36, indicating a potential technical oversell signal. The stock has fallen below its support level identified at €60.76, paving the way to a zone of vulnerability before the next resistance at €69.84. The RSI stands at 39, close to the 30 threshold generally associated with oversold conditions, although it has not yet reached it. The 50-day moving average (€64.87) and the 200-day moving average (€63.86) are both significantly above the current price, confirming a short-term trend break. Over three months, the performance is at -17.05%, while the stock still posts a gain of 9.25% over one year.
A Sparse Financial Calendar Until September
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The lack of immediate catalysts weighs on the stock. The next official date in the laboratory testing and analysis group's financial calendar is the publication of the 2026 half-year results, expected on September 18. Until then, investors have few operational milestones that could redirect the stock's momentum. In the healthcare sector, other comparable stocks are also in negative territory this Wednesday: Sanofi is down 0.75%, reflecting a cautious stance in the European pharmaceutical sector. Eurofins Scientific's beta of -0.08 also highlights a low historical correlation with the Paris market, making the stock's specific variations all the more visible. With a monthly volatility of 7.73, the range of movements remains high as the next financial publication approaches.
SectorSanté · Vaccins et laboratoires de recherche›Services médicaux
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: 1T2026
Key reported figures
Revenue: 1789M€
Guidance from the release
Eurofins a rencontré des vents contraires importants et temporaires.
Malgré une croissance organique modérée, la rentabilité et les marges progressent.
Risks mentioned
Baisse de la demande en raison de conditions climatiques défavorables en Amérique du Nord.
Rationalisation des contrats dans les diagnostics cliniques en Espagne et en Italie.
Opportunities identified
Lancement de nouveaux contrats renforçant notre portefeuille BioPharma.
Initiatives de digitalisation et amélioration du réseau de laboratoires.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.